RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells

Cancer Cell International

Volumn 15, Issue 1, 2015, Pages

  Zheng, Zhong ^a,b   Liu, Bingya ^c   Wu, Xiaohua ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gastric cancer; Multidrug resistance; P gp; Rac1; RhoGDI2

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOGDI2 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; GASTRIC CANCER CELL LINE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; UPREGULATION; VECTOR CONTROL;

EID: 84928042876     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-015-0190-4     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-8.
3. Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010;6(4):527-37.
4. Zheng Z, Li J, He X, Chen X, Yu B, Ji J, et al. Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2010;57(102-103):1106-12.
5. Cho HJ, Baek KE, Nam IK, Park SM, Kim IK, Park SH, et al. PLCgamma is required for RhoGDI2-mediated cisplatin resistance in gastric cancer. Biochem Biophys Res Commun. 2011;414(3):575-80.
6. Cho HJ, Baek KE, Park SM, Kim IK, Nam IK, Choi YL, et al. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 2011;311(1):48-56.
7. Cho HJ, Kim IK, Park SM, Baek KE, Nam IK, Park SH, et al. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer. 2014;135(7):1553-63.
8. Kim IK, Park SM, Cho HJ, Baek KE, Nam IK, Park SH, et al. 14-3-3sigma attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells. Oncotarget. 2013;4(11):2045-56.
9. Zheng Z, He XY, Li JF, Yu BQ, Chen XH, Ji J, et al. RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells. Oncology Letters. 2013;5(1):255-60.
10. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008;9(9):690-701.
11. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247-69.
12. Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J. 2005;390(Pt 1):1-9.
13. Zhang Y, Rivera Rosado LA, Moon SY, Zhang B. Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. J Biol Chem. 2009;284(19):12956-65.
14. Moissoglu K, McRoberts KS, Meier JA, Theodorescu D, Schwartz MA. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 2009;69(7):2838-44.
15. Agarwal NK, Chen CH, Cho H, Boulbes DR, Spooner E, Sarbassov DD. Rictor regulates cell migration by suppressing RhoGDI2. Oncogene. 2013;32(20):2521-6.
16. Griner EM, Theodorescu D. The faces and friends of RhoGDI2. Cancer Metastasis Rev. 2012;31(3-4):519-28.
17. Huang CY, Yang LC, Liu KY, Chang IC, Liao PH, Chou JI, et al. ZAK negatively regulates RhoGDIbeta-induced Rac1-mediated hypertrophic growth and cell migration. J Biomed Sci. 2009;16:56.
18. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis. 1999;20(14):2961-9.
19. Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, et al. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol Rep. 2006;15(5):1265-71.
20. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537-92.
21. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411-24.
22. Griner EM, Dancik GM, Costello JC, Owens C, Guin S, Edwards MG, et al. RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Mol Cancer Res. 2015;13(3):483-92.
23. Agarwal NK, Kazyken D, dos Sarbassov D. Rictor encounters RhoGDI2: the second pilot is taking a lead. Small GTPases. 2013;4(2):102-5.
24. Boulter E, Garcia-Mata R, Guilluy C, Dubash A, Rossi G, Brennwald PJ, et al. Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1. Nat Cell Biol. 2010;12(5):477-83.
25. Garcia-Mata R, Boulter E, Burridge K. The 'invisible hand': regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol. 2011;12(8):493-504.
26. Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A. 2009;106(14):5807-12.
27. Ota T, Maeda M, Okamoto M, Tatsuka M. Positive regulation of Rho GTPase activity by RhoGDIs as a result of their direct interaction with GAPs. BMC Syst Biol. 2015;9:3.
28. Wang YW, Qu Y, Li JF, Chen XH, Liu BY, Gu QL, et al. In vitro and in vivo evidence of metallopanstimulin-1 in gastric cancer progression and tumorigenicity. Clin Cancer Res. 2006;12(16):4965-73.
29. Yuen HF, Chan YP, Chan KK, Chu YY, Wong ML, Law SY, et al. Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer. 2007;97(10):1409-15.
30. Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2010;17(8):2213-21.